{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:18:52Z","timestamp":1789802332450,"version":"4.0.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring of mycophenolic acid (MPA) is limited due to the requirement for intensive pharmacokinetic sampling to assess the area under the curve (AUC). Limited sampling strategies (LSS) offer a practical alternative; however, enterohepatic recirculation (EHR) affects prediction accuracy and precision. This study is the first to develop LSS models capable of simultaneously predicting the AUC of MPA, its metabolites [mycophenolic acid glucuronide (MPAG) and acyl mycophenolic acid glucuronide (Acyl-MPAG)], and MPA EHR in kidney transplant recipients (KTRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Intensive pharmacokinetic sampling was conducted in 84 adult KTRs receiving mycophenolate mofetil. MPA AUC\n                      <jats:sub>0-12<\/jats:sub>\n                      was calculated, and MPA EHR was determined. During the development of the LSS models, a balanced representation of patients with high and low EHR was ensured. Multiple linear regression was used to develop AUC prediction models for MPA, MPAG, and Acyl-MPAG, as well as an EHR prediction model. The best models were selected based on prediction performance, the highest prediction concordance, and the shortest interval between the first and last samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Three models for AUC\n                      <jats:sub>0-12<\/jats:sub>\n                      prediction were identified, incorporating 4, 5, and 6 concentration timepoints. The LSS model with 6 concentrations demonstrated the best performance, with excellent prediction concordance (100% for MPA and MPAG, and 93% for Acyl-MPAG). The EHR prediction model included 4 concentrations and exhibited an \u223c80% prediction concordance. An online calculator was developed for these models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      The developed LSS models simultaneously predict MPA, MPAG, and Acyl-MPAG AUC\n                      <jats:sub>0-12<\/jats:sub>\n                      using the same timepoints with high accuracy and precision. MPA EHR can be predicted using 4 concentration timepoints. The inclusion of late concentration timepoints is essential for the high predictive performance of LSS models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Notation:<\/jats:title>\n                    <jats:p>clinicaltrials.gov, NCT04953715.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001336","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T14:02:46Z","timestamp":1746194566000},"page":"799-808","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Simultaneous Prediction of Area Under the Curves of Mycophenolic Acid and Its Metabolites and Enterohepatic Recirculation in Kidney Transplant Recipients"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-9980","authenticated-orcid":false,"given":"Moataz E.","family":"Mohamed","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Saqr","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Onyeaghala","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Texas Medical Branch, Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory P.","family":"Remmel","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Staley","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey R.","family":"Dorr","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"},{"name":"Division of Nephrology and Hypertension, School of Medicine, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levi","family":"Teigen","sequence":"additional","affiliation":[{"name":"Department of Food Science and Nutrition, University of Minnesota, St. Paul, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Guan","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Madden","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinical Trials Office, University of Minnesota, Minneapolis, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Munoz","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinical Trials Office, University of Minnesota, Minneapolis, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Texas Medical Branch, Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duy","family":"Vo","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Texas Medical Branch, Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"El-Rifai","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, School of Medicine, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Oetting","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J.","family":"Matas","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Israni","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Texas Medical Branch, Galveston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4145-7045","authenticated-orcid":false,"given":"Pamala A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"R1-20251107","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1015828802490","article-title":"Bioavailability improvement of mycophenolic acid through amino ester derivatization","volume":"7","author":"Lee","year":"1990","journal-title":"Pharm Res."},{"key":"R2-20251107","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ajt.2023.02.004","article-title":"OPTN\/SRTR 2021 annual data report: kidney","volume":"23","author":"Lentine","year":"2023","journal-title":"Am J Transpl."},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin Pharmacokinet."},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/ki.2013.517","article-title":"Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients","volume":"85","author":"Colom","year":"2014","journal-title":"Kidney Int."},{"key":"R5-20251107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2215\/CJN.05440610","article-title":"Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring","volume":"6","author":"De Winter","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"key":"R7-20251107","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0000000000000871","article-title":"Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology","volume":"43","author":"Bergan","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2011.01.002","article-title":"Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of the Transplantation Society consensus meeting","volume":"25","author":"Le Meur","year":"2011","journal-title":"Transpl Rev (Orlando)"},{"key":"R9-20251107","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/TP.0b013e3181744199","article-title":"Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review","volume":"85","author":"Knight","year":"2008","journal-title":"Transplantation"},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/FTD.0b013e318068619d","article-title":"Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring","volume":"29","author":"Budde","year":"2007","journal-title":"Ther Drug Monit."},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1185\/030079906X148481","article-title":"Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome","volume":"22","author":"Kaplan","year":"2006","journal-title":"Curr Med Res Opin."},{"key":"R12-20251107","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/00007691-200206000-00011","article-title":"Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients","volume":"24","author":"Shipkova","year":"2002","journal-title":"Ther Drug Monit."},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/clinchem\/45.3.419","article-title":"Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil","volume":"45","author":"Sch\u00fctz","year":"1999","journal-title":"Clin Chem."},{"key":"R14-20251107","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0041-1345(00)02424-6","article-title":"The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes","volume":"33","author":"Shipkova","year":"2001","journal-title":"Transpl Proc"},{"key":"R15-20251107","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0009-9120(99)00101-0","article-title":"Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?","volume":"33","author":"Wieland","year":"2000","journal-title":"Clin Biochem."},{"key":"R16-20251107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-200302000-00001","article-title":"Acyl glucuronide drug metabolites: toxicological and analytical implications","volume":"25","author":"Shipkova","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R17-20251107","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/pmic.200300836","article-title":"Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue","volume":"4","author":"Shipkova","year":"2004","journal-title":"Proteomics"},{"key":"R18-20251107","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1021\/acs.chemrestox.5b00315","article-title":"Toxicity of carboxylic acid-containing drugs: the role of acyl migration and CoA conjugation investigated","volume":"28","author":"Lassila","year":"2015","journal-title":"Chem Res Toxicol."},{"key":"R19-20251107","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.transproceed.2006.10.189","article-title":"Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?","volume":"39","author":"Arns","year":"2007","journal-title":"Transpl Proc."},{"key":"R20-20251107","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/FTD.0000000000001248","article-title":"Limited sampling strategies fail to accurately predict mycophenolic acid area under the curve in kidney transplant recipients and the impact of enterohepatic recirculation","volume":"47","author":"Mohamed","year":"2025","journal-title":"Ther Drug Monit."},{"key":"R21-20251107","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.1064","article-title":"Mycophenolic acid and its metabolites in kidney transplant recipients: a semimechanistic enterohepatic circulation model to improve estimating exposure","volume":"58","author":"Okour","year":"2018","journal-title":"J Clin Pharmacol."},{"key":"R23-20251107","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/jcph.125","article-title":"Limited sampling strategy of mycophenolic acid in adult kidney transplant recipients: influence of the post-transplant period and the pharmacokinetic profile","volume":"53","author":"Chaabane","year":"2013","journal-title":"J Clin Pharmacol."},{"key":"R24-20251107","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.ftd.0000211810.19935.44","article-title":"Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants","volume":"28","author":"Ting","year":"2006","journal-title":"Ther Drug Monit."},{"key":"R25-20251107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.11613\/BM.2015.015","article-title":"Understanding Bland Altman analysis","volume":"25","author":"Giavarina","year":"2015","journal-title":"Biochem Med (Zagreb)."},{"key":"R26-20251107","first-page":"342","article-title":"Folded empirical distribution function curves\u2014mountain plots","volume":"49","author":"Monti","year":"1995","journal-title":"Am Statistician"},{"key":"R28-20251107","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bcpt.13743","article-title":"Pharmacokinetics of free and total mycophenolic acid in paediatric and adult renal transplant recipients: exploratory analysis of the effects of clinical factors and gene variants","volume":"131","author":"Liu","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R29-20251107","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/FTD.0b013e31818b8244","article-title":"Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation","volume":"30","author":"Mino","year":"2008","journal-title":"Ther Drug Monit."},{"key":"R30-20251107","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/0091270009335003","article-title":"Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients","volume":"49","author":"Naito","year":"2009","journal-title":"J Clin Pharmacol."},{"key":"R31-20251107","doi-asserted-by":"crossref","first-page":"407","DOI":"10.18433\/jpps30505","article-title":"Limited sampling strategy for the estimation of mycophenolic acid and its acyl glucuronide metabolite area under the concentration-time curve in Japanese lung transplant recipients","volume":"22","author":"Tanaka","year":"2019","journal-title":"J Pharm Pharm Sci."},{"key":"R32-20251107","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/j.1600-6143.2007.01859.x","article-title":"Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients","volume":"7","author":"Heller","year":"2007","journal-title":"Am J Transpl."},{"key":"R33-20251107","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FTD.0000000000001066","article-title":"Volumetric absorptive microsampling to enhance the therapeutic drug monitoring of tacrolimus and mycophenolic acid: a systematic review and critical assessment","volume":"45","author":"Leino","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R34-20251107","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1111\/bcp.16182","article-title":"Clinical validation of two volumetric absorptive microsampling devices to support home-based therapeutic drug monitoring of immunosuppression","volume":"90","author":"Leino","year":"2024","journal-title":"Br J Clin Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:00:41Z","timestamp":1762542041000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001336","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"2025-01-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}